GleamWall
中文EN

TARS Tarsus Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1819790 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY86.3%
TTM net income YoY-765.3%
TTM EPS YoY-697.0%
Revenue 3-yr CAGR262.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-102.0%
Net margin-102.9%
FCF margin4.8%
EBITDA margin-101.7%

Returns

ROE-319.8%
ROA-135.0%
ROIC (approx.)-330.8%
Asset turnover1.31x

Leverage & solvency

Liabilities / assets79.4%
Debt / equity0.70x
Current ratio1.96x
Interest coverage-80.17x

Cash quality & payout

Operating cash flow / net income-0.07x
Accruals ratio-144.6%
Payout ratio—
Capex / revenue2.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$451.36M$182.95M
R&D expense$64.32M$53.39M
SG&A expense$427.32M$237.31M
Operating income-$70.97M-$120.57M
Interest expense$8.94M$7.85M
Pretax income-$64.36M-$115.55M
Income tax$2.06M$0
Net income-$66.42M-$115.55M
EBITDA-$70.11M-$119.88M
EPS (basic)-1.59-3.07
EPS (diluted)-1.59-3.07
Dividends declared per share0.000.00
Weighted avg. shares (diluted)41.78M37.60M
Balance sheet
Cash & equivalents$183.64M$97.38M
Short-term investments$233.63M$196.56M
Receivables$85.06M$46.76M
Inventory$4.37M$2.62M
Current assets$522.78M$356.70M
PP&E, net$11.66M$2.31M
Intangibles$7.37M$8.33M
Total assets$562.16M$376.99M
Current liabilities$135.69M$80.61M
Long-term debt$72.44M$71.84M
Total debt$72.44M$71.84M
Total liabilities$218.73M$152.46M
Shareholders' equity$343.43M$224.53M
Net debt-$111.20M-$25.54M
Shares outstanding42.55M38.35M
Cash flow statement
Operating cash flow-$12.45M-$83.03M
Capital expenditure$9.86M$1.57M
Free cash flow-$22.31M-$84.59M
Investing cash flow-$42.12M-$199.19M
Financing cash flow$143.39M$154.66M
Depreciation & amortization$855,000$685,000
Stock-based compensation$41.72M$27.82M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.